Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 263-271

  Hendrickson, Sher L ^a   Jacobson, Lisa P ^b   Nelson, George W ^c   Phair, John P ^d   Lautenberger, James ^a   Johnson, Randall C ^c   Kingsley, Lawrence ^e   Margolick, Joseph B ^b   Detels, Roger ^f   Goedert, James J ^g   O'Brien, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; AIDS restriction gene; Highly active antiretroviral therapy; Single nucleotide polymorphism

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 10; MULTIDRUG RESISTANCE PROTEIN 1; RANTES; RITONAVIR; SAQUINAVIR; STAVUDINE; STROMAL CELL DERIVED FACTOR 1; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; GLYCOPROTEIN P;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RESTRICTION GENE; ARTICLE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; GENE; GENE NUMBER; GENETIC ASSOCIATION; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS REPLICATION; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHEMOKINE CCL5; COHORT STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HIV-1; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 47049097878     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816fdc5f     Document Type: Article

References (60)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
2. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727-728.
3. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virolo-gical failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863-868.
4. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001;15:735-746.
5. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
6. Cozzi LA, Sabin CA, Staszewski S, et al. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis. 2000;181: 1143-1147.
7. Wensing AM, Boucher CAN. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003;5:140-155.
8. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451-458.
9. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535-551.
10. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA. 2002;99: 10002-10007.
11. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000;177:99-111.
12. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet. 2004; 36:565-574.
13. Javanbakht H, An P, Gold B, et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology. 2006;354:15-27.
14. Martin MP, Lederman MM, Hutcheson HB, et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol. 2004;78:14053-14056.
15. An P, Duggal P, Wang LH, et al. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 2007;3:e19.
16. Bashirova AA, Bleiber G, Qi Y, et al. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol. 2006;80:6757-6763.
17. Carrington M, O'Brien SJN. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535-551.
18. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
19. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 2004;101:4180-4185.
20. Kasten S, Goldwich A, Schmitt M, et al. Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur J Med Res. 2000;5:323-328.
21. O'Brien TR, McDermott DH, Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS. 2000;14:821-826.
22. Tang J, Kaslow RA. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS. 2003;17(Suppl 4):S51-S60.
23. Bogner JR, Lutz B, Klein HG, et al. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med. 2004;5:264-272.
24. Puissant B, Roubinet F, Massip P, et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retroviruses. 2006;22:153-162.
25. Wit FW, van Rij RP, Weverling GJ, et al. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002;186:1726-1732.
26. Passam AM, Zafiropoulos A, Miyakis S, et al. CCR2-64I and CXCL12 3#A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy. J Clin Virol. 2005;34:302-309.
27. Brumme ZL, Dong WW, Chan KJ, et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS. 2003;17:201-208.
28. Lathey JL, Tierney C, Chang SY, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis. 2001;184:1402-1411.
29. Daar ES, Lynn HS, Donfield SM, et al. Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression. J Infect Dis. 2005;192:1597-1605.
30. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA. 2000;97:14467-14472.
31. An P, Vlahov D, Margolick JB, et al. A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals. J Infect Dis. 2003;188:228-231.
32. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
33. Trkola A, Gordon C, Matthews J, et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal trans-duction pathway that enhances viral infectivity. J Virol. 1999;73:6370-6379.
34. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA. 2001; 98:5199-5204.
35. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 2000;14:2671-2678.
36. Ye P, Kourtis AP, Kirschner DEN. Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy. Clin Immunol. 2003;106:95-105.
37. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16(Suppl 1): S5-S37.
38. Srinivas RV, Middlemas D, Flynn P, et al. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother. 1998;42: 3157-3162.
39. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
40. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther. 1998;3:215-220.
41. Nasi M, Borghi V, Pinti M, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 2003;17:1696-1698.
42. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-36.
43. Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;19:371-380.
44. Verstuyft C, Marcellin F, Morand-Joubert L, et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 2005;19:2127-2131.
45. Detels R. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort. J Epidemiol. 1992;2:511-519.
46. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989;321:1141-1148.
47. Department of Health and Human Services/Henry J. Kaiser Family Foundation on Clinical Practices for the Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC; February 2002 revision.
48. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998;282:1907-1911.
49. Valdez H, Purvis SF, Lederman MM, et al. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. JAMA. 1999;282:734.
50. Guerin S, Meyer L, Theodorou I, et al. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2000;14:2788-2790.
51. Laurichesse JJ, Persoz A, Theodorou I, et al. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. HIV Med. 2007;8:213-219.
52. Brumme ZL, Henrick BM, Brumme CJ, et al. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antivir Ther. 2005;10:849-853.
53. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272: 1167-1170.
54. Ye P, Kazanjian P, Kunkel SL, et al. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med. 2004;143:310-319.
55. van Rij RP, de Roda Husman AM, Brouwer M, et al. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis. 1998;178:1806-1811.
56. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS. 2003;17:377-387.
57. Reeves JD, McKnight A, Potempa S, et al. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology. 1997;231:130-134.
58. Faure S, Meyer L, Genin E, et al. Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression. J Acquir Immune Defic Syndr. 2003;32:335-337.
59. McDermott DH, Fong AM, Yang Q, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111:1241-1250.
60. Haas DW, Wu H, Li H, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group Study. J Acquir Immune Defic Syndr. 2003;34:295-298.